The New Identified Biomarkers Determine Sensitivity to Immune Check-Point Blockade Therapies in Melanoma
OncoImmunology - United States
doi 10.1080/2162402x.2019.1608132
Full Text
Open PDFAbstract
Available in full text
Date
May 10, 2019
Authors
Publisher
Informa UK Limited